Incidence of alopecia in brain tumour patients treated with pencil scanning proton therapy and validation of existing NTCP models.

Brain tumor NTCP Proton therapy: radiation-induced alopecia

Journal

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
ISSN: 1879-0887
Titre abrégé: Radiother Oncol
Pays: Ireland
ID NLM: 8407192

Informations de publication

Date de publication:
26 Jul 2024
Historique:
received: 05 04 2024
revised: 19 07 2024
accepted: 22 07 2024
medline: 29 7 2024
pubmed: 29 7 2024
entrez: 28 7 2024
Statut: aheadofprint

Résumé

Radiation-induced alopecia (RIA) is one of the most frequent and upsetting cosmetic side effects after radiotherapy (RT) for brain cancer. We report the incidence of RIA in a cohort of brain tumours patients treated with Proton Therapy (PT) and externally validate published NTCP models of grade 2 (G2) RIA for their implementation in clinical practice. Data for patients treated for brain tumours with scanning beam PT between 2018 and 2022 were extracted. Acute, late and permanent RIA events were evaluated according to CTCAE 5.0. Lyman-Kutcher-Burman (LKB) and multivariable logistic regression (MLR) published models were computed from the relative dose-surface histogram of the scalp. External validity of models was assessed in terms of discrimination and calibration. In the 264 patients analysed, rates of any grade acute (≤90 days after PT completion), late (>90 days) and permanent RIA (persisting for> 12 months) were 61.8 %, 24.7 % and 14.4 %, respectively. In our independent cohort, LKB- and MLR-NTCP showed a good discrimination for G2 RIA (0.71≤ROC-AUC≤0.83) while model calibration was unsatisfactory possibly due to a different outcome evaluation between training and validation cohorts, as well as differences in clinical and treatment related variables between the two groups. Despite the reasonable sensitivity and specificity of the NTCP models for RIA in the validation cohort, our study emphasizes the significance of differences between the cohorts utilized for model development and validation. Specifically, variations in the reporting of clinical outcomes inevitably jeopardize the validation of NTCP models. A standardize and objective RIA scoring system is essential.

Sections du résumé

BACKGROUND AND PURPOSE OBJECTIVE
Radiation-induced alopecia (RIA) is one of the most frequent and upsetting cosmetic side effects after radiotherapy (RT) for brain cancer. We report the incidence of RIA in a cohort of brain tumours patients treated with Proton Therapy (PT) and externally validate published NTCP models of grade 2 (G2) RIA for their implementation in clinical practice.
METHODS METHODS
Data for patients treated for brain tumours with scanning beam PT between 2018 and 2022 were extracted. Acute, late and permanent RIA events were evaluated according to CTCAE 5.0. Lyman-Kutcher-Burman (LKB) and multivariable logistic regression (MLR) published models were computed from the relative dose-surface histogram of the scalp. External validity of models was assessed in terms of discrimination and calibration.
RESULTS RESULTS
In the 264 patients analysed, rates of any grade acute (≤90 days after PT completion), late (>90 days) and permanent RIA (persisting for> 12 months) were 61.8 %, 24.7 % and 14.4 %, respectively. In our independent cohort, LKB- and MLR-NTCP showed a good discrimination for G2 RIA (0.71≤ROC-AUC≤0.83) while model calibration was unsatisfactory possibly due to a different outcome evaluation between training and validation cohorts, as well as differences in clinical and treatment related variables between the two groups.
CONCLUSIONS CONCLUSIONS
Despite the reasonable sensitivity and specificity of the NTCP models for RIA in the validation cohort, our study emphasizes the significance of differences between the cohorts utilized for model development and validation. Specifically, variations in the reporting of clinical outcomes inevitably jeopardize the validation of NTCP models. A standardize and objective RIA scoring system is essential.

Identifiants

pubmed: 39069083
pii: S0167-8140(24)00732-1
doi: 10.1016/j.radonc.2024.110462
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

110462

Informations de copyright

Copyright © 2024 The Author(s). Published by Elsevier B.V. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

Simona Gaito (S)

Proton Clinical Outcomes Unit, The Christie Proton Beam Therapy Center, Manchester, United Kingdom; Division of Cancer Sciences, School of Medical Science, Faculty of Biology Medicine and Health, The University of Manchester, Manchester, United Kingdom.

Laura Cella (L)

Institute of Biostructures and Bioimaging, National Research Council, Naples, Italy. Electronic address: laura.cella@cnr.it.

Anna France (A)

Proton Clinical Outcomes Unit, The Christie Proton Beam Therapy Center, Manchester, United Kingdom.

Serena Monti (S)

Institute of Biostructures and Bioimaging, National Research Council, Naples, Italy.

Gillian Whitfield (G)

Division of Cancer Sciences, School of Medical Science, Faculty of Biology Medicine and Health, The University of Manchester, Manchester, United Kingdom; Proton Beam Therapy Centre. The Christie NHS Foundation Trust, Manchester, United Kingdom.

Peter Sitch (P)

Proton Clinical Outcomes Unit, The Christie Proton Beam Therapy Center, Manchester, United Kingdom; Proton Beam Therapy Centre. The Christie NHS Foundation Trust, Manchester, United Kingdom.

Neil Burnet (N)

Proton Beam Therapy Centre. The Christie NHS Foundation Trust, Manchester, United Kingdom.

Ed Smith (E)

Proton Clinical Outcomes Unit, The Christie Proton Beam Therapy Center, Manchester, United Kingdom; Division of Cancer Sciences, School of Medical Science, Faculty of Biology Medicine and Health, The University of Manchester, Manchester, United Kingdom; Proton Beam Therapy Centre. The Christie NHS Foundation Trust, Manchester, United Kingdom.

Giuseppe Palma (G)

Institute of Nanotechnology, National Research Council, Lecce, Italy.

Marianne Aznar (M)

Division of Cancer Sciences, School of Medical Science, Faculty of Biology Medicine and Health, The University of Manchester, Manchester, United Kingdom.

Classifications MeSH